andrew kaye, head of policy at macmillan cancer support said it was �shocking� that a cancer patient had to wait 541 days for treatment.. september 2014  (25).

cambridge's bluebird bio licenses delivery tech to novartis, gsk.

the news highlighted another factor in the chinese threat: regardless of the different regulatory framework, many researchers think the data they report is valid.. august 2012  (20)